NTRK1 and neoplasm: Sunitinib, functioning as a multitargeted tyrosine kinase inhibitor, impedes tumor cell growth and angiogenesis by targeting receptors such as platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), and KIT receptor tyrosine kinase (KIT) [15].